Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2312-2321

  Gianni, A M ^a   Siena, S ^a   Bregni, M ^a   Di Nicola, M ^a   Orefice, S ^a   Cusumano, F ^a   Salvadori, B ^a   Luini, A ^a   Greco, M ^a   Zucali, R ^a   Rilke, F ^a   Zambetti, M ^a   Valagussa, P ^a   Bonadonna, G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MELPHALAN; METHOTREXATE;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0031004064     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2312     Document Type: Article

References (34)

1. Bonadonna G, Valagussa P: Adjuvant systemic therapy for resectable breast cancer. J Clin Oncol 3:259-275, 1985
2. Jones SE, Moon TE, Bonadonna G, et al: Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol 10:387-395, 1987
3. Buzzoni R, Bonadonna G, Valagussa P, et al: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9:2134-2140, 1991
4. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542-547, 1995
5. Antman K, Gale RP: Advanced breast cancer: High-dose chemotherapy and bone marrow autotransplant. Ann Intern Med 108:570-574, 1988
6. Socinski MA, Cannistra SA, Elias A, et al: Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1:1194-1198, 1988
7. Duhrsen U, Villeval JL, Bojd J, et al: Effects of recombinant human granulocyte colony stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 72:2074-2081, 1988
8. Gianni AM, Siena S, Bregni M, et al: Granulocyte-macrophage colony-stimulating factor to harvest circulating haematopoietic stem cells for autotransplantation. Lancet 2:580-585, 1989
9. Siena S, Bregni M, Brando B, et al: Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide treated patients: Enhancement by intravenous recombinant human granulocyte-macrophage colony stimulating factor. Blood 74:1905-1914, 1989
10. Gianni AM: Where do we stand with respect to the use of peripheral blood progenitor cells? Ann Oncol 5:781-784, 1994
11. Siena S, Bregni M, Di Nicola M. et al: Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Ann Oncol 5:935-841, 1994
12. Peters WP: High-dose chemotherapy and autologous bone marrow support for breast cancer, in De Vita VT, Hellman S, Rosemberg SA (eds): Important Advances in Oncology, 1991. Philadelphia, PA, Lippincott, 1991, pp 135-150
13. Gianni AM, Bonadonna G: High dose chemo-radiotherapy for sensitive tumors: Is sequential better than concurrent drug delivery? Eur J Cancer Clin Oncol 25:1027-1030, 1989
14. Gianni AM, Siena S, Bregni M, et al: Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 2:645-653, 1991
15. Bonadonna G, Gianni AM: High-dose chemotherapy and autologous bone marrow transplantation for adjuvant treatment of poor-risk breast cancer. Oncol J Club 140:3-16, 1990
16. Gianni AM, Bregni M, Siena S, et al: Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 8:768-778, 1990
17. 2) cyclophosphamide cancer therapy. Ann Oncol 4:759-766, 1993
18. Siena S, Bregni M, Brando B, et al: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77:138-147, 1991
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 35:185-206, 1972
21. Cox DR: Regression models and life tables (with discussion). J R Stat Soc [B] 34:187-220, 1972
22. Miller RC: Survival Analysis. New York, NY, Wiley, 1981
23. Frei E III, Antman K, Teicher B, et al: Bone marrow autotransplantation for solid tumors - Prospects. J Clin Oncol 7:515-526, 1989
24. Vaughan WP, Karp JE, Burke PJ: Two-cycle timed sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 64:975-980, 1984
25. Karp JE, Donehover RC, Enterline JP, et al: In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood 73:24-30, 1989
26. Ung O, Longlands AO, Barraclough B, et al: Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement. J Clin Oncol 13:435-443, 1995
27. Lingos TI, Recht A, Vicini F, et al: Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 21:355-360, 1991
28. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993
29. De Graaf H, Willemse PHB, De Vries EGE, et al: Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur J Cancer 30A: 150-153, 1994
30. Ayash LJ, Elias A, Wheeler C, et al: Double dose-intensive chemotherapy with autologous bone marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: A feasibility study. J Clin Oncol 12:37-44, 1994
31. Crown J, Kritz A, Vahdat L, et al: Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol 11:1144-1149, 1993
32. Pittman KB, To LB, Bayly JL, et al: Non-haematological toxicity limiting the application of sequential high dose chemotherapy in patients with advanced breast cancer. Bone Marrow Transplant 10:535-540, 1992
33. Crown J, Raptis G, Vahdat L, et al: Rapid administration of sequential high dose cyclophosphamide, melphalan, thiotepa supported by filgrastim + peripheral blood progenitors in patients with metastatic breast cancer: A novel and very active treatment strategy. Proc Am Soc Clin Oncol 13:110, 1994 (abstr 242)
34. Tajita T, Tokuda J, Ohta M, et al: Role of autologous bone marrow transplantation in cancer chemotherapy. Low Temperature Med 15:44-50, 1989